Aaron T. Gerds

Cleveland Clinic — United States

Medicine · Health Sciences

40h-index6.6kcitations721works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(388), Acute Myeloid Leukemia Research(253), Chronic Myeloid Leukemia Treatments(246), Acute Lymphoblastic Leukemia research(92), Hematopoietic Stem Cell Transplantation(80)

Publications719 total

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.
PubMed·2026
Real-Time Kinetics of Interleukin-6 (IL-6) Predict Cytokine Release Syndrome (CRS) in Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy for relapsed/refractory B-cell Malignancies.
Transplantation and Cellular Therapy·2026Open Access
Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemia
Leukemia & lymphoma/Leukemia and lymphoma·2026
Supplementary Figure S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S1 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S5 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Table S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Table S1 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S9 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S7 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S2 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Table S2 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Table S4 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S4 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S6 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Supplementary Figure S8 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
2025Open Access
Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis
Blood·2025Open Access
The Impact of the number of cytogenetic abnormalities on clinical outcomes in Acute Myeloid Leukemia with complex karyotype
Blood·2025
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia
Blood·2025Open Access
A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
Blood·2025Open Access
page 1 of 36Next →

Frequent Co-authors

Ruben A. Mesa(17), Srđan Verstovšek(16), Vikas Gupta(15), Stephen T. Oh(12), Moshe Talpaz(11), Claire Harrison(11), Jean‐Jacques Kiladjian(11), Mikkael A. Sekeres(11), Jason Gotlib(10), Brady L. Stein(9), Jaroslaw P. Maciejewski(9), Sudipto Mukherjee(9), Anjali S. Advani(9), Matt Kalaycio(9), Ronald Sobecks(9), Bart L. Scott(8), Alessandro M. Vannucchi(8), Hetty E. Carraway(8), Aziz Nazha(8), Raajit K. Rampal(8)